Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alterity Therapeutics ( (ATHE) ) has issued an announcement.
On April 29, 2025, Alterity Therapeutics Limited announced changes in the interests of its directors in securities. The changes, which took place on April 24, 2025, involved the acquisition of listed options by directors Peter Marks and Lawrence Gozlan. These changes reflect internal adjustments in the company’s governance and may impact the company’s strategic direction and stakeholder interests.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
Alterity Therapeutics faces financial challenges with declining revenues and persistent losses, significantly impacting its financial performance and valuation score. Despite these challenges, the stock shows strong upward momentum, with positive technical indicators suggesting potential short-term opportunities. However, investors should be cautious of the overbought RSI and high risk associated with its financial instability.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise based in Melbourne, Australia. The company operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases.
YTD Price Performance: -6.70%
Average Trading Volume: 444,318
Technical Sentiment Signal: Sell
Current Market Cap: $46.94M
See more insights into ATHE stock on TipRanks’ Stock Analysis page.